CLEOPATRA: Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

⚠️ Updated analysis. The primary endpoint (independent review facility-assessed progression-free survival) was previously reported: HR 0·62 (95% CI 0·51–0·75; p<0·001). This prespecified end-of-study analysis reports updated overall survival and safety at median follow-up of 99·9 months.

Primary endpoint (IRF-assessed PFS, previously reported): HR 0·62 (95% CI 0·51–0·75; p<0·001) Key secondary (overall survival): 57·1 vs 40·8 months — HR 0·69 (95% CI 0·58–0·82; p<0·0001) Safety signal: Grade 3–4 neutropenia in 49% of pertuzumab arm; febrile neutropenia serious AE in 11% of pertuzumab arm

📱 Clinic quick reference: Mobile version — save for point-of-care use

Clinical Bottom Line

Adding pertuzumab to trastuzumab and docetaxel for the first-line treatment of HER2-positive metastatic breast cancer produces a durable and clinically meaningful survival advantage. With over eight years of follow-up, this end-of-study analysis confirms that the overall survival benefit first reported at interim analysis is sustained, with more than a third of patients in the pertuzumab arm alive at eight years compared to roughly one quarter in the control arm. For patients with HER2-positive metastatic breast cancer who have not received prior chemotherapy in the metastatic setting, this triplet remains the reference first-line regimen.

The treatment landscape for HER2-positive metastatic breast cancer has continued to evolve since CLEOPATRA's initial publication. Antibody-drug conjugates such as trastuzumab deruxtecan have reshaped the second-line and beyond settings, and newer agents are being studied in earlier lines. However, the pertuzumab-trastuzumab-docetaxel combination established by CLEOPATRA continues to anchor the first-line standard of care in current guidelines and remains the benchmark against which novel first-line approaches are measured.

From a safety perspective, the long-term toxicity profile was consistent with what was known from earlier analyses. No new safety signals emerged with extended follow-up. Cardiac safety — a key concern with HER2-directed therapies — remained reassuring, with only one new serious adverse event suggestive of congestive heart failure since the previous analysis. The myelosuppressive effects of the regimen, particularly neutropenia and febrile neutropenia, remain the most important acute toxicities to manage.

Trial Overview

Study Design

• Trial name and registration: CLEOPATRA, NCT00567190
• Design: Phase 3, double-blind, randomised, placebo-controlled trial; this publication is the prespecified end-of-study (descriptive) analysis
• Randomization: 1:1, stratified by geographical region (Asia, Europe, North America, or South America) and previous treatment status (neoadjuvant or adjuvant chemotherapy received vs not)
• Setting: HER2-positive breast cancer, first-line metastatic
• Enrollment period: February 12, 2008 to July 7, 2010

This publication reports the prespecified end-of-study analysis of the CLEOPATRA trial. The primary endpoint (IRF-assessed PFS) was previously reported in the original publication [1], and the confirmatory overall survival analysis was subsequently published. All analyses in this report are descriptive.

Mechanism of Action

Pertuzumab is a HER2/neu receptor antagonist — a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the HER2 receptor. By binding to this domain, pertuzumab blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3, and HER4. This inhibits ligand-initiated intracellular signaling through two major signal pathways: mitogen-activated protein (MAP) kinase and phosphoinositide 3-kinase (PI3K). Pertuzumab also mediates antibody-dependent cell-mediated cytotoxicity (ADCC). By targeting a different epitope on HER2 than trastuzumab, the two antibodies provide complementary mechanisms of HER2 blockade [2].

Patient Population

• Key eligibility: Patients aged 18 years or older with HER2-positive metastatic breast cancer, ECOG performance status 0 or 1, left ventricular ejection fraction (LVEF) of at least 50% at baseline, and no previous chemotherapy or biological therapy for metastatic disease. Prior neoadjuvant or adjuvant chemotherapy with or without trastuzumab was permitted if there was a minimum 12-month interval between completion of all therapy and metastatic disease diagnosis. Up to one hormonal treatment for metastatic disease was allowed but no concurrent hormonal therapy before disease progression.
• Biomarker selection: HER2-positive (immunohistochemistry 3+ or FISH-positive)
• Sample size flow: 1,196 patients screened → 808 randomised (402 pertuzumab arm, 406 placebo arm) → 808 in the intention-to-treat population → 804 in the safety population (408 pertuzumab arm, 396 placebo arm)

Baseline Characteristics

Detailed baseline characteristics were published previously in the original CLEOPATRA publication and were reported as similar between the two groups. The current end-of-study analysis does not reproduce the full baseline characteristics table. For complete demographic and disease characteristic data, see Reference [1].

Treatment Protocol

Experimental Arm: Pertuzumab, Trastuzumab, and Docetaxel (n=402 randomised; safety population n=408)

Pertuzumab plus trastuzumab plus docetaxel, all given intravenously every 3 weeks.

• Dose and schedule: Pertuzumab loading dose 840 mg, then 420 mg maintenance; trastuzumab loading dose 8 mg/kg, then 6 mg/kg maintenance; docetaxel 75 mg/m², escalating to 100 mg/m² if tolerated. All given intravenously every 3 weeks.
• Treatment duration: Pertuzumab and trastuzumab given until disease progression or unmanageable toxic effects; docetaxel for at least 6 cycles (more at investigators' discretion)
• Median treatment duration: Not reported in this publication. Median number of treatment cycles was 24·0.

• Maximum number of cycles received: 167

• Median relative dose intensity: Not reported in this publication

Control Arm: Placebo, Trastuzumab, and Docetaxel (n=406 randomised; safety population n=396)

Placebo plus trastuzumab plus docetaxel, all given intravenously every 3 weeks.

• Dose and schedule: Placebo (matched to pertuzumab) loading dose 840 mg equivalent, then 420 mg equivalent maintenance; trastuzumab loading dose 8 mg/kg, then 6 mg/kg maintenance; docetaxel 75 mg/m², escalating to 100 mg/m² if tolerated. All given intravenously every 3 weeks.
• Treatment duration: Placebo and trastuzumab given until disease progression or unmanageable toxic effects; docetaxel for at least 6 cycles (more at investigators' discretion)
• Median treatment duration: Not reported in this publication. Median number of treatment cycles was 15·0.
• Maximum number of cycles received: 67

Crossover

• Permitted: Yes — after the second interim overall survival analysis confirmed a statistically significant survival improvement (July 2012), investigators were unblinded and patients in the placebo group without disease progression were offered crossover to pertuzumab.
• N crossed over: 50 patients crossed from the placebo to the pertuzumab group
• Trigger: The second interim OS analysis confirmed significant OS improvement
• Analysis approach: ITT; crossover patients were analysed in the placebo group for overall survival (conservative approach). For safety analyses, crossover patients were counted in the placebo group up to the day before the first pertuzumab dose. Post-crossover safety data are reported separately.

Efficacy Outcomes

The primary endpoint of this trial (independent review facility-assessed progression-free survival) was reported in the original publication [1]. Adding pertuzumab to trastuzumab and docetaxel significantly improved IRF-assessed median progression-free survival compared with placebo, trastuzumab, and docetaxel: HR 0·62 (95% CI 0·51–0·75; p<0·001). The current prespecified end-of-study analysis, with a median follow-up of 99·9 months (IQR 92·9–106·4) in the pertuzumab group and 98·7 months (IQR 90·9–105·7) in the placebo group, reports the following updated results. All analyses in this report are descriptive.

Key Secondary Endpoint: Overall Survival

Definition: Time from randomisation to death from any cause Analysis population: Intention-to-treat (N=808) Data cutoff: November 23, 2018

In the intention-to-treat population, there were 235 (58%) overall survival events in 402 patients in the pertuzumab group and 280 (69%) overall survival events in 406 patients in the placebo group.

Pertuzumab, trastuzumab, and docetaxel: Median overall survival 57·1 months (95% CI 50–72) Placebo, trastuzumab, and docetaxel: Median overall survival 40·8 months (95% CI 36–48) Comparison: HR 0·69 (95% CI 0·58–0·82; p<0·0001)

Overall Survival Landmark Rates (ITT Population)

Secondary Endpoint: Investigator-Assessed Progression-Free Survival

Definition: Time from randomisation to disease progression or death, assessed by investigator Analysis population: Intention-to-treat (N=808)

There were 304 (76%) investigator-assessed progression-free survival events in 402 patients in the pertuzumab group (296 disease progressions and 8 deaths without previous disease progression) and 329 (81%) events in 406 patients in the placebo group (312 disease progressions and 17 deaths without previous disease progression).

Pertuzumab, trastuzumab, and docetaxel: Median investigator-assessed PFS 18·7 months (95% CI 17–22) Placebo, trastuzumab, and docetaxel: Median investigator-assessed PFS 12·4 months (95% CI 10–14) Comparison: HR 0·69 (95% CI 0·59–0·81; p<0·0001)

Exploratory Endpoints

Investigator-assessed PFS 8-year landmark rate: 16% in the pertuzumab group vs 10% in the placebo group (from Figure 2B).

Long-Term Responders

In this analysis, 99 patients were classified as long-term responders in the pertuzumab group (235 non-long-term responders) and 53 in the placebo group (286 non-long-term responders).

Post-Hoc Analysis: Patients with Prior Trastuzumab

In the subgroup of patients who previously received trastuzumab, median overall survival was 53·8 months (95% CI 41–71) in the pertuzumab group and 46·6 months (95% CI 30–70) in the placebo group (HR 0·86, 95% CI 0·51–1·43; post-hoc analysis).

Safety

Safety Population

The safety population consisted of 408 patients in the pertuzumab group and 396 patients in the placebo group (pre-crossover). Safety analyses were based on treatment received; crossover patients were counted in the placebo group up to the day before the first pertuzumab dose.

Safety Summary

Many standard summary safety metrics (any AE, grade ≥3 AE, serious AE, treatment-related AE, dose reduction, dose interruption) were not individually reported in this end-of-study publication. The following metrics were available:

• Treatment-related deaths: 5 (1%) of 408 patients in the pertuzumab group and 6 (2%) of 396 patients in the placebo group
• Discontinuation from HER2-targeted treatment due to adverse event: 39 patients in the pertuzumab group and 24 patients in the placebo group
• Adverse events leading to death during treatment phase: 8 (2%) in the pertuzumab group and 12 (3%) in the placebo group
• Most common treatment-related serious adverse events: Febrile neutropenia — 46 (11%) in the pertuzumab group; febrile neutropenia 19 (5%) and neutropenia 19 (5%) in the placebo group

Median number of treatment cycles was 24·0 in the pertuzumab group and 15·0 in the placebo group.

Grade ≥3 Adverse Events of Clinical Significance

The most common grade 3–4 adverse event was neutropenia: 200 (49%) of 408 patients in the pertuzumab group and 183 (46%) of 396 patients in the placebo group.

Adverse Events of Special Interest

Cardiac Safety

Since the previous analysis, there was only one new serious adverse event suggestive of congestive heart failure (pertuzumab group) and one new symptomatic left ventricular dysfunction (pertuzumab group post-crossover). The long-term cardiac safety profile remained reassuring with extended follow-up, consistent with earlier reports.

Deaths

Overall survival events (ITT population):

• Pertuzumab group: 235 (58%) of 402 patients
• Placebo group: 280 (69%) of 406 patients

Deaths in safety population (pre-crossover):

• Pertuzumab group: 238 (58%) of 408 patients
• Placebo group: 261 (66%) of 396 patients

Deaths due to disease progression (safety population):

• Pertuzumab group: 215 (53%) of 408 patients
• Placebo group: 240 (61%) of 396 patients

Adverse events leading to death during treatment phase:

• Pertuzumab group: 8 (2%)
• Placebo group: 12 (3%)

Treatment-related deaths:

• Pertuzumab group: 5 (1%)
• Placebo group: 6 (2%)

Deaths without prior disease progression (ITT population):

• Pertuzumab group: 8 patients
• Placebo group: 17 patients

Crossover population (n=50):

• Deaths: 14 (28%) of 50, of which 12 (24%) were due to disease progression

Subgroup Analyses

Overall Survival by Prespecified Subgroups

The overall survival benefit with pertuzumab-based therapy was consistent across most prespecified subgroups, with point estimates favoring the pertuzumab arm. Two notable findings merit attention: patients with non-visceral disease showed no apparent benefit (HR 1·08, 95% CI 0·72–1·62), and patients from Asia showed a numerically smaller benefit (HR 0·85, 95% CI 0·63–1·16) compared with other regions, though neither subgroup was sufficiently powered for independent conclusions.

These subgroup analyses were prespecified and were not powered for formal statistical comparisons. Results should be interpreted as hypothesis-generating.

Key Comparator Trials

Cross-trial comparisons are limited by differences in patient populations, trial designs, and endpoints. These data are presented for context, not for direct statistical comparison.

Contextual Notes

CLEOPATRA established the combination of pertuzumab, trastuzumab, and docetaxel as the first-line standard of care for HER2-positive metastatic breast cancer. Subsequent attempts to dethrone this regimen in the first line have generally been unsuccessful. The MARIANNE trial [4] evaluated T-DM1 with or without pertuzumab against trastuzumab plus a taxane and showed non-inferiority but failed to demonstrate superiority for T-DM1-based regimens, reinforcing the CLEOPATRA standard.

More recently, trastuzumab deruxtecan (T-DXd) has dramatically altered the second-line and later treatment landscape for HER2-positive metastatic breast cancer based on the DESTINY-Breast03 trial. Whether T-DXd-based regimens can supplant the CLEOPATRA regimen in the first-line setting is being investigated in the DESTINY-Breast09 trial [5]. Until those data mature, the pertuzumab-trastuzumab-docetaxel combination remains the reference first-line approach. The eight-year survival data from this end-of-study analysis — with 37% of pertuzumab-treated patients alive at eight years — set a high bar for any successor regimen to surpass.

Grey Zones and Unanswered Questions

• Non-visceral disease: The subgroup of patients without visceral disease showed no apparent OS benefit with the addition of pertuzumab (HR 1·08, 95% CI 0·72–1·62). This subgroup was small (n=178) and not powered for independent conclusions, but it raises the question of whether dual HER2 blockade is equally beneficial across all disease presentations — or whether a subset of patients with lower disease burden might be adequately served by trastuzumab and chemotherapy alone.

• Patients with prior trastuzumab exposure: A growing proportion of patients presenting with metastatic HER2-positive breast cancer will have received pertuzumab-based therapy in the (neo)adjuvant setting (e.g., following APHINITY). CLEOPATRA enrolled patients who could have received prior trastuzumab (with a 12-month treatment-free interval), but the post-hoc analysis of this subgroup showed a numerically smaller OS benefit (HR 0·86, 95% CI 0·51–1·43). The optimal first-line treatment for patients who relapse after pertuzumab-based adjuvant therapy remains undefined.

• Chemotherapy backbone: CLEOPATRA used docetaxel as the chemotherapy backbone. Whether other chemotherapy partners (paclitaxel, nab-paclitaxel, vinorelbine) combined with pertuzumab and trastuzumab would produce equivalent efficacy is supported by limited data from smaller studies but has never been tested in a definitive randomized trial. Clinical practice has varied considerably on this point.

• Duration of HER2-directed therapy: In the pertuzumab arm, the median number of treatment cycles was 24·0 and the maximum reached 167 cycles. Whether indefinite continuation of dual HER2-targeted therapy until progression is optimal, or whether a fixed duration or de-escalation strategy could maintain efficacy while reducing treatment burden and cost, is unknown. This question is particularly relevant for the long-term responders identified in this analysis.

• The Asia subgroup: Patients from Asia showed a numerically smaller OS benefit (HR 0·85, 95% CI 0·63–1·16) compared with other regions. Whether this reflects differences in subsequent therapy access, pharmacogenomic differences, or statistical chance is unclear. This observation warrants further investigation but should not drive individual treatment decisions.

Clinical Implications

Where This Fits in the Treatment Sequence

The pertuzumab-trastuzumab-docetaxel combination remains the first-line standard of care for HER2-positive metastatic breast cancer per NCCN guidelines [3]. This end-of-study analysis, with the longest follow-up of any randomized phase 3 trial in this setting, reinforces that position. With a median overall survival exceeding four and a half years and an 8-year survival rate of 37%, this regimen provides a benchmark for any emerging first-line competitor.

Practical Considerations

Pertuzumab and trastuzumab are administered intravenously every 3 weeks and can be given on the same day. Docetaxel is typically administered for at least 6 cycles, with the option to continue longer at investigator discretion — though in clinical practice, most patients transition to maintenance dual HER2-targeted therapy after completing taxane-based chemotherapy. Cardiac monitoring with LVEF assessment is required per prescribing information [2]. The median number of treatment cycles in the pertuzumab arm was 24·0, reflecting prolonged maintenance therapy in many patients.

Neutropenia management is critical during the chemotherapy-containing phase: grade 3–4 neutropenia occurred in 49% of the pertuzumab arm, and febrile neutropenia was the most common treatment-related serious adverse event (11%). Growth factor support should be considered per institutional guidelines. Diarrhoea was more common with pertuzumab (grade 3: 10% vs 5%), consistent with the known side-effect profile of pertuzumab.

Impact of Crossover on Results

50 patients crossed from the placebo arm to the pertuzumab arm after the second interim OS analysis confirmed a statistically significant survival improvement (July 2012). The overall survival analysis used the ITT approach: crossover patients remained in the placebo group. This conservative analysis likely underestimates the true magnitude of the OS difference, as patients in the placebo group who crossed over to pertuzumab may have derived survival benefit that is attributed to the control arm. No crossover-adjusted analysis (e.g., RPSFT or IPCW) was reported in this publication.

Post-Progression Options

After coming off study treatment, 275 patients in the pertuzumab group and 301 in the placebo group received subsequent breast cancer treatment. In the current treatment landscape, second-line options for HER2-positive metastatic breast cancer following first-line pertuzumab-trastuzumab-based therapy include trastuzumab deruxtecan (based on DESTINY-Breast03), with T-DM1 and other regimens available in subsequent lines per NCCN guidelines [3].

Regulatory and Guideline Status

Regulatory

• FDA: Pertuzumab (Perjeta) was granted accelerated approval in June 2012 for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease, based on the CLEOPATRA PFS data. Regular approval followed based on the confirmed OS benefit. Pertuzumab is also approved in the neoadjuvant and adjuvant settings for HER2-positive early breast cancer.
• EMA: Pertuzumab (Perjeta) is approved in the European Union for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

⚠️ Regulatory status verified as of March 2026. Confirm current approval status and labeled indications before clinical use at FDA.gov or EMA.europa.eu.

Guidelines

• NCCN: Pertuzumab in combination with trastuzumab and a taxane is a Category 1 preferred first-line regimen for HER2-positive recurrent or metastatic breast cancer per NCCN Clinical Practice Guidelines in Oncology: Breast Cancer [3].
• ESMO: The pertuzumab-trastuzumab-taxane combination is recommended as the preferred first-line treatment for HER2-positive advanced breast cancer.

Companion Diagnostics

HER2-positive status must be confirmed by immunohistochemistry (IHC 3+) or fluorescence in situ hybridization (FISH-positive). FDA-approved companion diagnostic tests include the HercepTest and PathVysion HER2 DNA Probe Kit, among others. HER2 testing should be performed in a CLIA-certified laboratory using validated assays.

About the Author

Andrew Stevenson is the founder and systems architect of kill-cancer.com, a clinical intelligence platform delivering structured, source-traced oncology trial analysis to practicing clinicians. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces directly to its source publication. Zero calculation. Zero editorializing. Zero hallucination.

Five siblings lost to cancer built the urgency. The engineering builds the trust.

📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum

This article is intended for healthcare professionals only. It is not medical advice and should not be used as a substitute for professional clinical judgment. Treatment decisions should be made in consultation with qualified healthcare providers based on individual patient circumstances.

All trial data presented in this article are sourced directly from the published clinical trial report and its supplementary materials. Numbers are reproduced exactly as reported; no calculations, derivations, or estimates have been performed.

Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability.

Comparator trial data presented in Section 8 are sourced from their respective published reports and are provided for contextual purposes only. Cross-trial comparisons have inherent limitations and should not be interpreted as direct statistical comparisons.

References

1. Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519–530. doi:10.1016/S1470-2045(19)30863-0
2. Perjeta (pertuzumab) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
4. Perez EA, Barrios C, Eiermann W, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol. 2017;35(2):141–148.
5. DESTINY-Breast09 (NCT04784715). ClinicalTrials.gov. Accessed March 2026.